Follow
Anna Emde
Anna Emde
Verified email at weizmann.ac.il
Title
Cited by
Cited by
Year
Dysregulated mi RNA biogenesis downstream of cellular stress and ALS‐causing mutations: a new mechanism for ALS
A Emde, C Eitan, LL Liou, RT Libby, N Rivkin, I Magen, I Reichenstein, ...
The EMBO journal 34 (21), 2633-2651, 2015
2052015
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer
H Liu, C Zang, A Emde, MD Planas-Silva, M Rosche, A Kühnl, CO Schulz, ...
European journal of pharmacology 591 (1-3), 43-51, 2008
1592008
mi RNA s at the interface of cellular stress and disease
A Emde, E Hornstein
The EMBO journal 33 (13), 1428-1437, 2014
1272014
Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer
T Knösel, A Emde, K Schlüns, Y Chen, K Jürchott, M Krause, M Dietel, ...
Neoplasia 7 (8), 741-747, 2005
1032005
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
A Emde, WJ Köstler, Y Yarden
Critical reviews in oncology/hematology 84, e49-e57, 2012
532012
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions
CR Pradeep, A Zeisel, WJ Köstler, M Lauriola, J Jacob-Hirsch, ...
Oncogene 31 (31), 3569-3583, 2012
452012
Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance
A Emde, G Mahlknecht, K Maslak, B Ribba, M Sela, K Possinger, ...
Translational oncology 4 (5), 293-300, 2011
362011
Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth
A Emde, CR Pradeep, DA Ferraro, N Ben-Chetrit, M Sela, B Ribba, Z Kam, ...
Oncogene 30 (14), 1631-1642, 2011
252011
Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
S Wilson, M Tod, A Ouerdani, A Emde, Y Yarden, A Adda Berkane, ...
CPT: pharmacometrics & systems pharmacology 4 (12), 720-727, 2015
192015
Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
A Emde, WJ Köstler, Y Yarden
Crit Rev Oncol Hematol 84 (Suppl 1), e49-e57, 2012
172012
Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines
AM Emde, K Maslak, H Liu, AE Reles, K Possinger, J Eucker
Journal of Clinical Oncology 25 (18_suppl), 14050-14050, 2007
52007
Therapie des Mammakarzinoms
J Eucker, A Emde, K Possinger
Der Internist 12 (47), 1223-1228, 2006
42006
DOWNREGULATION OF miR-218 MAY BE USED AS A BIOMARKER FOR HUMAN ALS
E Hornstein, A Chen, I Reichenstein, AM Emde
US Patent App. 14/671,848, 2015
32015
Methods of diagnosing and treating motor neuron diseases and other cellular stress-related diseases
E Hornstein, AM Emde
US Patent 10,159,670, 2018
22018
Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: A new mechanism for ALS
AM Emde
PQDT-Global, 2016
12016
Honokiol (from magnolia)
H Liu, C Zang, A Emde, MD Planas-Silva, M Rosche, A Kühnl, CO Schulz, ...
Eur J Pharmacol 591 (1-3), 43-51, 2008
12008
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions
CR Pradeep, A Zeisel, WJ Köstler, M Lauriola, J Jacob-Hirsch, ...
Oncogene 43 (17), 1317-1317, 2024
2024
Quantification of Dicer Activity in Mammalian Cell Lysates Using a Non-radioactive Fluorescence Method
A Emde, N Rivkin, MA Behlke, E Hornstein
MicroRNA Technologies, 21-27, 2017
2017
Thesis for the degree
AM Emde
2016
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
LHY Liu HongYu, CB Zang, A Emde, MD Planas-Silva, M Rosche, ...
2008
The system can't perform the operation now. Try again later.
Articles 1–20